|Bid||11.05 x 900|
|Ask||13.03 x 3000|
|Day's Range||11.11 - 11.96|
|52 Week Range||4.02 - 13.45|
|Beta (5Y Monthly)||1.23|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 10, 2021 - Mar 15, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.83|
HACKENSACK, NJ / ACCESSWIRE / March 5, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery through innovative pharmacology, biomarker and data platforms, today announced it will report its financial and operational results for the third quarter ended January 31, 2021, on Thursday, March 11, 2021, after market close.
Champions Oncology, Inc. (CSBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HACKENSACK, NJ / ACCESSWIRE / February 22, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR) a leading global oncology technology solutions provider transforming drug discovery through innovative pharmacology, biomarker, and data platforms, is pleased to announce the appointment of Rob Brainin to its Board of Directors.